Valuation: Cardiol Therapeutics Inc.

Market Cap 162M 113M 103M 95.26M 86.05M 10.66B 168M 1.15B 454M 5.72B 426M 417M 18.11B P/E 2026 *
-3.86x
P/E 2027 * -4.52x
Enterprise Value 143M 100M 91.01M 84.08M 75.95M 9.41B 148M 1.01B 401M 5.05B 376M 368M 15.99B EV / Sales 2026 *
-
EV / Sales 2027 * 77.9x
Free-Float
93.13%
Yield 2026 *
-
Yield 2027 * -
Nov. 12 Cardiol Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
Sep. 23 Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead of Schedule and Expands Pivotal Trial CI
Sep. 23 Cardiol Therapeutics Inc. Achieves MAVERIC Enrollment Target And Expands Pivotal Trial Evaluating CardiolRx CI
Aug. 12 Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
May. 11 Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
May. 07 Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment MT
May. 07 Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis MT
May. 07 Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association MT
May. 07 Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association CI
Apr. 28 Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S. MT
Apr. 28 Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx CI
Apr. 01 Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial MT
Apr. 01 Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis RE
1 day-5.44%
1 week-6.08%
Current month-14.20%
1 month-12.03%
3 months-44.62%
6 months-23.20%
Current year+6.11%
1 week 1.38
Extreme 1.38
1.52
1 month 1.29
Extreme 1.29
1.71
Current year 1.22
Extreme 1.225
3.23
1 year 1.22
Extreme 1.225
3.23
3 years 1.07
Extreme 1.07
4.26
5 years 0.61
Extreme 0.61
4.26
10 years 0.61
Extreme 0.61
8.49
Manager TitleAgeSince
Chief Executive Officer - 2017-01-18
Director of Finance/CFO - 2018-08-15
Chief Operating Officer - 2020-12-02
Director TitleAgeSince
Director/Board Member - 2017-12-14
Director/Board Member - 2017-01-18
Chairman - 2021-07-06
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 Option

Chairman

25,000 0.0214%
9/8/26 Option

Chairman

-25,000 0.0214%
8/28/26 Option

Chief Technology Officer

-70,000 0.0599%
Change 5-day change 1-year change 3-year change Capi.($)
-5.44%-6.08%-3.47%+21.93% 113M
-1.29%-3.91%+51.98%+69.06% 65.56B
-0.09%+2.79%+12.54%+95.02% 60.41B
+0.63%+1.64%+23.11%+89.70% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
-3.15%-16.63%+146.30%+685.27% 36.09B
+0.23%+2.14%+14.85%+46.22% 36.7B
+2.35%-3.61%+80.65%+60.70% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -0.68%-2.08%+32.20%+161.74% 41B
Weighted average by Cap. -0.27%-1.58%+35.56%+151.44%

Financials

2026 *2027 *
Net sales - 2M 1.4M 1.27M 1.17M 1.06M 131M 2.07M 14.11M 5.59M 70.43M 5.24M 5.13M 223M
Net income -41.4M -28.93M -26.29M -24.29M -21.94M -2.72B -42.86M -292M -116M -1.46B -109M -106M -4.62B -37.65M -26.31M -23.91M -22.09M -19.95M -2.47B -38.97M -266M -105M -1.33B -98.74M -96.65M -4.2B
Net Debt -19.05M -13.31M -12.1M -11.18M -10.09M -1.25B -19.72M -134M -53.25M -671M -49.96M -48.9M -2.13B -6.59M -4.61M -4.19M -3.87M -3.49M -433M -6.83M -46.52M -18.43M -232M -17.29M -16.93M -736M
Projected Income Statement - Annual - Cardiol Therapeutics Inc.
Logo Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Employees
18
Date Price Change Volume
26-11-16 CA$1.390 -5.44% 53,341
26-11-13 CA$1.470 0.00% 39,578
26-11-12 CA$1.470 +0.68% 85,641
26-11-11 CA$1.460 +1.39% 45,715
26-11-10 CA$1.440 -2.70% 80,119
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cardiol Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.390CAD
Average target price
7.000CAD
Spread / Average Target
+403.60%
  1. Stock Market
  2. Stocks
  3. CRDL Stock